

Alexander N Shoushtari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6255084/publications.pdf>

Version: 2024-02-01

74
papers

11,424
citations

117625

34
h-index

98798

67
g-index

77
all docs

77
docs citations

77
times ranked

18039
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.	21.4	2,702
2	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <i>Nature Medicine</i> , 2017, 23, 703-713.	30.7	2,473
3	OncoKB: A Precision Oncology Knowledge Base. <i>JCO Precision Oncology</i> , 2017, 2017, 1-16.	3.0	1,266
4	Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 226-235.	1.6	458
5	Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. <i>New England Journal of Medicine</i> , 2021, 385, 1196-1206.	27.0	376
6	<i>PTEN</i> Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma. <i>JCO Precision Oncology</i> , 2017, 1, 1-15.	3.0	275
7	Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. <i>Human Pathology</i> , 2015, 46, 357-365.	2.0	252
8	Recurrent activating mutations of G-protein-coupled receptor <i>CYSLTR2</i> in uveal melanoma. <i>Nature Genetics</i> , 2016, 48, 675-680.	21.4	236
9	The efficacy of anti- <i>PD-1</i> agents in acral and mucosal melanoma. <i>Cancer</i> , 2016, 122, 3354-3362.	4.1	236
10	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.	28.9	223
11	Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. <i>Nature Communications</i> , 2021, 12, 729.	12.8	212
12	Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT). <i>Journal of Clinical Oncology</i> , 2018, 36, 1232-1239.	1.6	207
13	Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis. <i>Oncologist</i> , 2016, 21, 848-854.	3.7	154
14	The association between tumor mutational burden and prognosis is dependent on treatment context. <i>Nature Genetics</i> , 2021, 53, 11-15.	21.4	139
15	Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis. <i>Cancer Discovery</i> , 2021, 11, 1212-1227.	9.4	139
16	Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade. <i>Journal of Clinical Oncology</i> , 2020, 38, 1655-1663.	1.6	138
17	Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 5869-5878.	7.0	131
18	Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma. <i>JAMA Oncology</i> , 2018, 4, 98.	7.1	125

#	ARTICLE	IF	CITATIONS
19	Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. <i>Nature Biotechnology</i> , 2022, 40, 499-506.	17.5	110
20	Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab. <i>Clinical Cancer Research</i> , 2017, 23, 2972-2980.	7.0	106
21	GNAQ and GNA11 mutations in uveal melanoma. <i>Melanoma Research</i> , 2014, 24, 525-534.	1.2	99
22	Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation. , 2015, 3, 22.		95
23	Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy. <i>Ophthalmology</i> , 2017, 124, 1788-1798.	5.2	95
24	GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma. <i>Cell Reports</i> , 2018, 22, 2455-2468.	6.4	75
25	Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 5993-6000.	7.0	70
26	Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. , 2020, 8, e000331.		66
27	Localized sinonasal mucosal melanoma: Outcomes and associations with stage, radiotherapy, and positron emission tomography response. <i>Head and Neck</i> , 2016, 38, 1310-1317.	2.0	65
28	Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw260.	6.3	56
29	LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	54
30	Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy. <i>Cancer</i> , 2019, 125, 884-891.	4.1	43
31	MRI radiomic features are associated with survival in melanoma brain metastases treated with immune checkpoint inhibitors. <i>Neuro-Oncology</i> , 2019, 21, 1578-1586.	1.2	42
32	Combined immunotherapy and radiation for treatment of mucosal melanomas of the lower genital tract. <i>Gynecologic Oncology Reports</i> , 2016, 16, 42-46.	0.6	40
33	Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma. <i>Melanoma Research</i> , 2017, 27, 57-64.	1.2	39
34	Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade. <i>Annals of Surgical Oncology</i> , 2020, 27, 1180-1188.	1.5	39
35	Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature. <i>Oncologist</i> , 2020, 25, 140-149.	3.7	38
36	Loss of polycomb repressive complex 1 activity and chromosomal instability drive uveal melanoma progression. <i>Nature Communications</i> , 2021, 12, 5402.	12.8	34

#	ARTICLE	IF	CITATIONS
37	A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor. <i>Investigational New Drugs</i> , 2019, 37, 282-290.	2.6	32
38	A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma. <i>Melanoma Research</i> , 2016, 26, 272-277.	1.2	31
39	Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience. <i>Oncologist</i> , 2019, 24, e196-e197.	3.7	31
40	Combined Inhibition of G1±q and MEK Enhances Therapeutic Efficacy in Uveal Melanoma. <i>Clinical Cancer Research</i> , 2021, 27, 1476-1490.	7.0	29
41	Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study). <i>Journal of Clinical Oncology</i> , 2022, 40, 1059-1067.	1.6	26
42	Rates of <i>ERBB2</i> Alterations across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an <i>ERBB2</i> -Amplified Acral Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 5815-5819.	7.0	25
43	Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas. <i>Clinical Cancer Research</i> , 2021, 27, 2226-2235.	7.0	25
44	Lung-only melanoma: UV mutational signature supports origin from occult cutaneous primaries and argues against the concept of primary pulmonary melanoma. <i>Modern Pathology</i> , 2020, 33, 2244-2255.	5.5	23
45	Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study. <i>British Journal of Dermatology</i> , 2022, 187, 401-410.	1.5	21
46	Treatment of Uveal Melanoma. <i>Cancer Treatment and Research</i> , 2016, 167, 281-293.	0.5	18
47	Leveraging Systematic Functional Analysis to Benchmark an <i>In Silico</i> Framework Distinguishes Driver from Passenger MEK Mutants in Cancer. <i>Cancer Research</i> , 2020, 80, 4233-4243.	0.9	18
48	DCE-MRI perfusion predicts pseudoprogression in metastatic melanoma treated with immunotherapy. <i>Journal of Neuro-Oncology</i> , 2020, 146, 339-346.	2.9	17
49	Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. , 2022, 10, e003853.		16
50	Isolated Abducens Nerve Palsy Following Pembrolizumab. <i>Neuro-Ophthalmology</i> , 2020, 44, 182-185.	1.0	15
51	Patient perspectives on ipilimumab across the melanoma treatment trajectory. <i>Supportive Care in Cancer</i> , 2017, 25, 2155-2167.	2.2	14
52	PD-1 Blockade in Chinese versus Western Patients with Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 4171-4173.	7.0	13
53	Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer. , 2015, 3, .		12
54	Are our patients doing better? A single institution experience of an evolving management paradigm for sinonasal mucosal melanoma. <i>Oral Oncology</i> , 2021, 112, 105006.	1.5	12

#	ARTICLE	IF	CITATIONS
55	Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma. <i>Cancers</i> , 2022, 14, 2638.	3.7	12
56	Hepatic abnormalities identified by staging MRI and accuracy of MRI of patients with uveal melanoma. <i>British Journal of Ophthalmology</i> , 2019, 103, 1266-1271.	3.9	8
57	Association Between Toxic Effects and Survival in Patients With Cancer and Autoimmune Disease Treated With Checkpoint Inhibitor Immunotherapy. <i>JAMA Oncology</i> , 2022, 8, 1352.	7.1	8
58	Novel Treatment Targets in Sarcoma: More Than Just the GIST. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e488-e495.	3.8	7
59	Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab. , 2021, 9, e003395.		7
60	Refractive Shifts and Changes in Corneal Curvature Associated With Antibody-Drug Conjugates. <i>Cornea</i> , 2022, 41, 792-801.	1.7	6
61	Adjuvant PD-1 Blockade in Resected Melanoma: Is Preventing Recurrence Enough?. <i>Cancer Discovery</i> , 2022, 12, 599-601.	9.4	6
62	Training Oncologists in the Time of COVID-19. <i>Oncologist</i> , 2020, 25, 546-547.	3.7	5
63	Specific human endogenous retroviruses predict metastatic potential in uveal melanoma. <i>JCI Insight</i> , 2022, 7, .	5.0	5
64	Quality of Life Concerns in Patients with Uveal Melanoma after Initial Diagnosis. <i>Ocular Oncology and Pathology</i> , 2020, 6, 184-195.	1.0	4
65	Incorporating VEGF Blockade Into a Shifting Treatment Paradigm for Mucosal Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 867-869.	1.6	4
66	Primary tumor volume as a predictor of distant metastases and survival in patients with sinonasal mucosal melanoma. <i>Head and Neck</i> , 2020, 42, 3316-3325.	2.0	3
67	546-Results from Phase Ib study of tebentafusp (tebe) in combination with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM). , 2021, 9, A576-A576.		3
68	Monitoring vulvar melanoma response to combined immunotherapy and radiotherapy with <i>in vivo</i> reflectance confocal microscopy. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 768-770.	0.8	2
69	538-Updated survival of patients with previously treated metastatic uveal melanoma who received tebentafusp. , 2021, 9, A568-A568.		2
70	About Face: Molecular Aberrations in Head and Neck Mucosal Melanomas. <i>Clinical Cancer Research</i> , 2019, 25, 3473-3475.	7.0	1
71	Metastatic melanoma concurrent to the urinary bladder and endometrium: Case report. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2021, , .	1.8	1
72	Combination intravitreal melphalan and bevacizumab for cutaneous metastatic melanoma to the vitreous and retina. <i>American Journal of Ophthalmology Case Reports</i> , 2022, 26, 101519.	0.7	1

#	ARTICLE	IF	CITATIONS
73	Urethral Melanoma – Clinical, Pathological and Molecular Characteristics. Bladder Cancer, 2022, 8, 291-301.	0.4	1
74	Risk of non-acral cutaneous melanoma after the diagnosis of acral melanoma. British Journal of Dermatology, 2022, , .	1.5	0